Home >> Marketplace Directory >> T2 Bacteria Panel study results, 1/16

T2 Bacteria Panel study results, 1/16

image_pdfCreate PDF

 

January 2016—T2 Biosystems presented data at the AMP annual meeting on its investigational T2Bacteria Panel. The data demonstrate the ability of T2Bacteria to provide rapid and sensitive identification of six sepsis-causing bacteria, directly from whole blood, with limits of detection as low as 1 CFU/mL. The six clinically relevant bacteria included in the panel are Staphylococcus aureus, Enterococcus faecium, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii.

The T2Bacteria Panel is being developed to provide a species-specific result in three to five hours, direct from whole blood, with no need for culture. Similar to the FDA-cleared T2Candida Panel, the T2Bacteria Panel will run on the fully automated T2Dx instrument. To date, the T2Candida Panel has demonstrated 91.1 percent sensitivity, 99.4 percent specificity, and limit of detection as low as 1 CFU/mL. Published data indicate that the T2Bacteria Panel, to achieve similar performance, would need to achieve a limit of detection below 10 CFU/mL for each species, which the company said was demonstrated in this study.

T2 Biosystems, 781-457-1200

CAP TODAY
X